Literature DB >> 9844819

Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase.

F Guilhot1, L Lacotte-Thierry.   

Abstract

Interferon-alpha has been shown to induce complete haematologic responses in chronic myelogenous leukemia patients and also cytogenetic responses. There is a clear correlation between cytogenetic responses and survival improvement. There is not a unique mechanism of action of IFN-alpha. IFN-alpha acts directly against leukemic cells and there are also other mechanisms of action such as immune stimulation, gene regulation and growth factors or interleukin stimulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9844819

Source DB:  PubMed          Journal:  Hematol Cell Ther        ISSN: 1269-3286


  5 in total

Review 1.  Development of an effective therapy for chronic myelogenous leukemia.

Authors:  David W Woessner; Carol S Lim; Michael W Deininger
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

2.  Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.

Authors:  Jorge Cortes; Alfonso Quintás-Cardama; Dan Jones; Farhad Ravandi; Guillermo Garcia-Manero; Srdan Verstovsek; Charles Koller; Jody Hiteshew; Jenny Shan; Susan O'Brien; Hagop Kantarjian
Journal:  Cancer       Date:  2010-09-30       Impact factor: 6.860

3.  Cardiovascular Manifestations of Myeloproliferative Disorders: A Review of the Literature.

Authors:  Muhammad Wasif Saif; Umer Khan; Bernard R Greenberg
Journal:  Hosp Physician       Date:  1999-07

4.  Cardiac Complications of Myeloproliferative Disorders.

Authors:  Muhammad Wasif Saif; Umer Khan; Bernard R Greenberg
Journal:  Resid Staff Physician       Date:  2001-07

5.  PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal.

Authors:  Shreya Kanodia; Eric Wieder; Sijie Lu; Moshe Talpaz; Gheath Alatrash; Karen Clise-Dwyer; Jeffrey J Molldrem
Journal:  PLoS One       Date:  2010-07-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.